Eculizumab as Primary Therapy for Active Antibody-Mediated Rejection of Renal Allografts: A Matter of Timing, Severity, and Donor-Specific Antibodies.
Sign Up to like & getrecommendations! Published in 2019 at "Transplantation"
DOI: 10.1097/tp.0000000000002640
Abstract: D increased utilization of paired kidney exchange and implementation in the United States of a new system for allocation of deceased donor kidneys granting waiting list priority to highly sensitized transplant candidates, those candidates with… read more here.
Keywords: posttransplantation; amr; active amr; antibody mediated ... See more keywords
Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical transplantation"
DOI: 10.1111/ctr.13908
Abstract: INTRODUCTION Chronic active antibody-mediated rejection (cAMR) is a major determinant of late allograft failure. Rituximab/immunoglobulins (IVIg) + plasma exchange (PLEX) showed controversial results in cAMR treatment. Tocilizumab (TCZ), a humanized anti-interleukin 6 receptor antibody, has… read more here.
Keywords: first line; chronic active; antibody; active antibody ... See more keywords
Chronic‐active antibody‐mediated rejection with or without donor‐specific antibodies has similar histomorphology and clinical outcome – a retrospective study
Sign Up to like & getrecommendations! Published in 2018 at "Transplant International"
DOI: 10.1111/tri.13154
Abstract: Chronic‐active antibody‐mediated rejection (c‐aABMR) is defined as histological evidence of chronic endothelial injury (cg), also known as transplant glomerulopathy, and either microvascular inflammation (MVI) or positivity for C4d. Importantly, the presence of donor‐specific antibodies (DSA)… read more here.
Keywords: mediated rejection; chronic active; study; active antibody ... See more keywords